AstraZeneca's Selumetinib Receives the US FDA's Breakthrough Therapy Designation for Neurofibromatosis Type 1
Shots:
- The BT Designation follows the P-II SPRINT trial assessing selumetinib as a monothx (PO) in paediatric patients- aged three years or older with inoperable NF1-related PN
- The ninth BT designation is granted to the AstraZeneca for the MEK 1/2 inhibitor and the results will further lead to expedited regulatory review
- Selumetinib is a MEK 1/2 inhibitor also received the US FDA’s ODD to treat NF1 in Feb 2018 and the European Medicines Agency in Aug 2018. In 2017- AstraZeneca and MSD signed a co-development and co-commercialization agreement for selumetinib
Click here to read full press release/ article
Ref: AstraZeneca | Image: AstraZeneca
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com